IFM Investors Pty Ltd Purchases 41,263 Shares of Pfizer Inc. $PFE

Key Points

• IFM Investors Pty Ltd increased its stake in Pfizer Inc. by 3.8% in Q2, holding over 1.1 million shares valued at approximately $27.3 million.
• Multiple analysts have adjusted their price targets for Pfizer, with Morgan Stanley raising its target to $33.00 and Berenberg Bank lowering it to $25.00, indicating mixed opinions on the stock's performance.
• Pfizer reported a 10.3% revenue growth year-over-year for the last quarter, with earnings per share exceeding analyst forecasts at $0.78.

IFM Investors Pty Ltd raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.8% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,127,143 shares of the biopharmaceutical company's stock after buying an additional 41,263 shares during the period. IFM Investors Pty Ltd's holdings in Pfizer were worth $27,322,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. AHL Investment Management Inc. lifted its position in shares of Pfizer by 3.2% in the 2nd quarter. AHL Investment Management Inc. now owns 94,702 shares of the biopharmaceutical company's stock worth $2,296,000 after purchasing an additional 2,920 shares during the period. Stolper Co lifted its position in shares of Pfizer by 7.5% in the 2nd quarter. Stolper Co now owns 55,477 shares of the biopharmaceutical company's stock worth $1,345,000 after purchasing an additional 3,888 shares during the period. Charter Oak Capital Management LLC lifted its position in shares of Pfizer by 4.3% in the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock worth $258,000 after purchasing an additional 444 shares during the period. Trust Point Inc. lifted its position in shares of Pfizer by 28.6% in the 2nd quarter. Trust Point Inc. now owns 31,992 shares of the biopharmaceutical company's stock worth $775,000 after purchasing an additional 7,116 shares during the period. Finally, Carderock Capital Management Inc. purchased a new stake in shares of Pfizer in the 2nd quarter worth about $78,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

PFE traded up $0.15 during trading hours on Monday, hitting $24.18. The company's stock had a trading volume of 44,650,963 shares, compared to its average volume of 45,254,059. The business's 50-day moving average price is $24.63 and its 200-day moving average price is $24.20. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The stock has a market cap of $137.47 billion, a price-to-earnings ratio of 12.85, a P/E/G ratio of 0.78 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the previous year, the business posted $0.60 earnings per share. Pfizer's quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer's payout ratio is 91.49%.

Analyst Upgrades and Downgrades

PFE has been the subject of several research analyst reports. Bank of America raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday. Citigroup lifted their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Finally, Berenberg Bank lowered their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.